Telehealth Visits Provide Early Detection, More Treatment Options and Better Chance of Survival August 1 is World Lung Cancer Awareness Day, a global initiative to raise awareness to the fact that lung cancer is the most common cause of cancer…
Research by investigators at Mayo Clinic Cancer Center suggests that physicians should screen patients with lung cancer for MET amplification/overexpression before determining a treatment strategy. Their findings are published Cancer Discovery, a journal of the American Association for Cancer Research.
The National Cancer Institute has awarded the Lung Cancer Metabolism Working Group at Moffitt Cancer Center with a Research Program Project Grant (P01CA250984). The grant, which will provide more than $10.2 million over five years, will support team research with a focus on investigating lung cancer metabolism.
A new study by Dana-Farber Cancer Institute researchers has given scientists their first look at the genomic landscape of tumors that have grown resistant to drugs targeting the abnormal KRASG12C protein. Their work shows that, far from adopting a common route to becoming resistant, the cells take a strikingly diverse set of avenues, often several at a time. The findings, reported online today in the New England Journal of Medicine, underscore the need for new drugs that inhibit KRAS differently than current agents do.
A new University of Kentucky College of Medicine study will examine how policies that restrict the sale of flavored tobacco products including menthol cigarettes impact health disparities among vulnerable populations.
Immune cells that normally repair tissues in the body can be fooled by tumors when cancer starts forming in the lungs and instead help the tumor become invasive, according to a surprising discovery reported by Mount Sinai scientists in Nature in June.
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer.
A team of researchers from the NUS Department of Biomedical Engineering and Institute for Health Innovation & Technology has developed a novel blood test called ExoSCOPE that could tell doctors whether cancer treatment is working for a patient, within 24 hours after the treatment. This will enable doctors to customise the treatment plan to improve patients’ chances of recovery.
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer, according to researchers from The University of Texas MD Anderson Cancer Center.
The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial led by Washington University School of Medicine in St. Louis. The drug is designed to shut down the effects of the mutation, which is found in about 13% of patients with lung adenocarcinoma, a common type of non-small-cell lung cancer.
In patients with non-small cell Lung Cancer (NSCLC), the presence of either high chronic inflammation, or procalcitonin levels in the blood as a response to bacterial infection, both predict a poor response to treatment with immune checkpoint blockade.
New research from Washington University School of Medicine in St. Louis has found that postponing lung cancer surgery for more than 12 weeks from the date of diagnosis with a CT scan is associated with a higher risk of recurrence and death.
A new innovation that holds promise to fight lung cancer is now in use at University Hospitals Cleveland Medical Center.
Cleveland Clinic cancer researchers are involved with more than 50 studies that’ll be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, June 4—8, 2021. Key research from Cleveland Clinic focuses on advancements in the prevention and…
A metabolic inhibitor drug, IACS-6274, developed by MD Anderson’s Therapeutics Discovery division, is well-tolerated and showed early signs of anti-tumor activity in a Phase I trial being presented at the 2021 ASCO Annual Meeting.
Memorial Sloan Kettering Cancer Center (MSK) today announced a $20 million gift from the Ge Li & Ning Zhao Family Foundation to support lung cancer research and the development of new therapies to treat this disease.
For AI to continue to transform cancer diagnoses, researchers will have to prove that the success of their machine-learning tools can be reproduced from site to site and among different patient populations. Biomedical engineering researchers at Case Western Reserve University say they doing just that. They say they have demonstrated that their novel algorithms for distinguishing between benign and malignant lung cancer nodules on CT scan images from one site can now be successfully reproduced with patients from other sites and locations.
Telehealth Visits Provide Early Detection, More Treatment Options and Better Chance of Survival
The combination approach uses immune checkpoint inhibitors with ATRA, a safe medication that is widely used to treat leukemia.
MD Anderson and Boehringer Ingelheim have expanded their joint Virtual Research and Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer.
Medical researchers from Case Western Reserve University, New York University (NYU), and University Hospitals have been awarded a five-year, $3 million National Cancer Institute grant to develop and apply artificial intelligence (AI) tools for predicting which lung cancer patients will respond to immunotherapy.
The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.
Each year in the U.S., about 30 million hospitalizations occur in individuals 18 and older. Of these, more than 7 million are current cigarette smokers whose average hospital stay is several days. Researchers say that starting smoking cessation therapy during hospitalization and maintaining high adherence post-discharge can markedly improve permanent quit rates in these patients with minimal to no side effects. Cessation therapy also should include long-term counseling and at least 90 days of a prescription drug, specifically, varenicline.
STS—in collaboration with the GO2 Foundation for Lung Cancer and the American College of Radiology—formally requested that CMS update its coverage policies to reflect the new USPSTF lung cancer screening guidelines.
A high rate of genetic mutations within a tumor, known as high tumor mutation burden, was only useful for predicting immunotherapy responses in a subset of cancer types, suggesting that this may not reliably be used as a universal biomarker.
Nasser Hanna, M.D., can provide expertise on the new guidelines for lung cancer screening recently issued by the U.S. Preventive Service Task Force. The USPSTF recommends yearly low-dose CT screening for those who are at high risk of developing lung…
To help develop the latest treatment methods and expand cancer care service, Thomas Daniels, MD, has been appointed service chief of the Department of Radiation Oncology at Perlmutter Cancer Center–Sunset Park in Brooklyn.
In a new article published in Clinical Cancer Research, Moffitt Cancer Center researchers show that various subtypes of lung cancer cells activate different signaling pathways in response to KRASG12C inhibitor treatment. These results may help identify potential combination therapy approaches and guide treatment decisions for lung cancer patients in the future.
Doctors and healthcare workers may one day use a machine learning model, called deep learning, to guide their treatment decisions for lung cancer patients, according to a team of Penn State Great Valley researchers.
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.
Structural racism thwarts a large proportion of black patients from receiving appropriate lung cancer care, resulting in worse outcomes and shorter lifespans than white patients with the disease, according to research presented at the 57th Annual Meeting of The Society of Thoracic Surgeons.
DALLAS – Jan. 25, 2021 – Small cell lung cancer (SCLC) cells are missing a surface protein that triggers an immune response, allowing them to hide from one of the body’s key cancer defenses, a new study led by UT Southwestern researchers suggests. The findings, reported online today in Cancer Research, a journal of the American Association for Cancer Research, could lead to new treatments for SCLC, which has no effective therapies.
Researchers at Canada’s McMaster University have established in lab settings that a novel combination of two forms of immunotherapy can be highly effective for treating lung cancer, which causes more deaths than any other form of cancer.
Credentialed press representatives are invited to attend The Society of Thoracic Surgeons VIRTUAL 57th Annual Meeting. This interactive, fully digital experience—expected to be unlike anything that cardiothoracic surgery has experienced to date—will feature thought-provoking lectures, practice-changing science, and cutting-edge techniques and technologies.
DALLAS – Jan. 5, 2021 – Researchers at the Children’s Medical Center Research Institute at UT Southwestern (CRI) have discovered a new metabolic vulnerability in a highly aggressive form of non-small cell lung cancer (NSCLC). These findings could pave the way for new treatments for patients with mutations in two key genes – KRAS and LKB1. Patients whose tumors contain both of these mutations, known as KL tumors, have poor outcomes and usually do not respond to immunotherapy.
Based on results of a clinical trial led by Yale Cancer Center researchers, the U.S. Food and Drug Administration has approved osimertinib for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations, which occurs in about 10 percent of patients.
Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, has been selected as the 2020 Clinical Research Award recipient by the Association of Community Cancer Centers for significantly and positively impacting oncology patients, their families, and the broader oncology community.
Reporting on how deferred care worsened outcomes for lung cancer patients when the COVID-19 pandemic first surged in the spring of 2020, researchers from the University of Cincinnati explained that they have identified a framework that could help people with serious health conditions keep up their appointments during the current surge. The study has been selected for the 2020 Southern Surgical Association Program and published as an “article in press” on the Journal of the American College of Surgeons website in advance of print.
UCLA scientists describe a new combination therapy that suppresses the MAPK pathway by holding cancer-driving proteins in a death grip. This combination of two small molecules has the potential to treat not only BRAF mutated melanoma but also additional aggressive subtypes of cancers, including melanoma, lung, pancreatic and colon cancers that harbor common mutations in cancer genes called RAS or NF1.
NYU Langone Health’s Perlmutter Cancer Center, a National Cancer Institute–designated Comprehensive Cancer Center, in partnership with NYU Langone Hospital–Brooklyn is growing its state-of-the-art lung cancer care in New York City’s largest borough with a new expansion of treatment and screening services.
Researchers at the UCLA Jonsson Comprehensive Cancer Center found patients with a particular type of human leukocyte antigen (HLA), a protein scaffold involved in presenting pieces of proteins described as peptides to the immune system, were particularly likely to benefit from immunotherapy.
An Indiana University Melvin and Bren Simon Comprehensive Cancer Center researcher has been awarded a five-year, $2.9 million grant from the National Cancer Institute to develop a drug that could make radiation therapy far more effective.
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) .
Lung cancer is one of the most common cancers in the U.S. and accounts for roughly 25% of all cancer deaths. Patrick Ryan, MS, from Texas A&M University, and his research team found that treating cultured lung cancer cells with blood collected from contracting muscles—muscles that were exercised—did not grow as much as untreated cells.
With Lung Cancer Awareness Month upon us, Indiana University Melvin and Bren Simon Comprehensive Cancer Center’s scientists, physician-scientists, and staff are available to offer expertise in treatment innovations, the biology of lung cancers, research initiatives, and tips for successful smoking…
UCLA Health has helped drive monumental advances in the treatment of lung cancer – increasing survival rates in the nation’s leading cause of cancer deaths.
African American patients with lung cancer are still less likely to receive the most effective treatment for a common type of early stage lung cancer.
The American Academy of Dermatology named board-certified dermatologist Brittany Smirnov, DO, FAAD, a Patient Care Hero for her role in diagnosing and treating a patient with stage IV metastatic lung cancer.
Researchers with the Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have secured $4 million in funding from the National Institutes of Health (NIH)/National Cancer Institute (NCI) to establish an HIV-associated Malignancy Research Center focused on lung cancer in East Africa.
Researchers from the Icahn School of Medicine at Mount Sinai will receive more than $7.3 million from the National Cancer Institute (NCI) as part of the NCI’s new Serological Sciences Network (SeroNet), one of the largest coordinated national efforts to study immunology and SARS-CoV-2, the virus that causes COVID-19. Mount Sinai was selected as one of only four Capacity Building Centers and one of eight Centers of Excellence as part of this new network.